Cosibelimab / UNLOXYT for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

As of August 2026, MARA’s assessment finds Cosibelimab / UNLOXYT’s reimbursement risk concentrated in clinical effectiveness, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs evidence quality and robustness: how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 165 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The pivotal evidence is from a phase I study with no randomized comparator. ORR is comparable to established PD-1 inhibitors, but no superiority or noninferiority can be established.

Does the economic case hold at the expected price? — Cost effectiveness

No economic model or ICER was identified for cosibelimab.

Is there quality-of-life evidence payers weigh? — Quality of life

No published HRQoL data or validated instruments were identified for cosibelimab.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Safety profile is well-characterized with manageable AEs, but no comparative safety data is available.

Was the drug compared against what payers expect? — Comparator Selection

The pivotal study is phase I with no comparator, and comparator selection is not described.

Is the population defined the way payers need it? — Patient Population and Subgroups

The study population is representative of older, checkpoint-naïve patients, but lacks representation of several clinically complex groups.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Cosibelimab fits into the existing treatment setting for advanced disease without requiring new diagnostics or major pathway changes.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use information is presented.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The evidence is from a phase I, open-label, single-arm study with no randomized comparator, limiting robustness.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty due to the uncontrolled design and absence of comparative data.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.